Biotinylated Human CD20/MS4A1 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02552P-100UG

Biotinylated Human CD20 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Biotinylated Human CD20/MS4A1 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02552P-100UG
Collections: Car-nk targets proteins, High-quality recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Biotinylated Human CD20/MS4A1 Protein is expressed from E.coli with His tag and Avi tag at the C-Terminus.It contains Ile141-Ser188. |
Purity | > 95% as determined by Tris-Bis PAGE |
Accession | P11836 |
Target Symbol | CD20/MS4A1 |
Synonyms | MS4A1;CD20;MS4A-1;B-lymphocyte surface antigen B1;Bp35;Leukocyte surface antigen Leu-16;Membrane-spanning 4-domains subfamily A member 11 |
Species | Human |
Expression System | E. coli |
Tag | C-His-Avi |
Expression Range | Ile141-Ser188 |
Mol. Weight | The protein has a predicted MW of 16.8 kDa same as Tris-Bis PAGE result. |
Form | Liquid |
Formulation | Supplied as 0.22um filtered solution in 20mM PB, 10% Glycerol (pH 7.0). |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Biotinylated Human CD20, His Tag at 1ug/ml (100ul/well) on the streptavidin precoated plate (5ug/ml). Dose response curve for Anti-CD20 Antibody, hFc Tag with the EC50 of 0.12ug/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Valid for 12 months from date of receipt when stored at -80°C.; Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
Shipping | Shipped with dry ice. |
Gene Background | B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. |